Nasdaq26d
SeaStar Medical Receives FDA Approval for SCD-ADULT Study Funded by $3.6 Million NIH Grant
FDA approves SeaStar Medical's SCD-ADULT study ... the condition of patients awaiting left ventricular assist device (LVAD) implantation, potentially offering significant advancements in treating ...
Yahoo Finance26d
FDA Approves Feasibility Study with SeaStar Medical’s Selective Cytopheretic Device in Adults with Cardiorenal Syndrome
The FDA’s Center for Biologics Evaluation and Research (CBER) granted Breakthrough Device Designation for the SCD in cardiorenal syndrome with LVAD in September 2023. “Oftentimes patients with ...
Business Insider26d
FDA Approves Feasibility Study with SeaStar Medical’s Selective Cytopheretic Device in Adults with Cardiorenal Syndrome
The FDA’s Center for Biologics Evaluation and Research (CBER) granted Breakthrough Device Designation for the SCD in cardiorenal syndrome with LVAD in ... regulatory approval of its SCD product ...
Yahoo Finance26d
FDA Approves Feasibility Study with SeaStar Medical’s Selective Cytopheretic Device in Adults with Cardiorenal Syndrome
The FDA’s Center for Biologics Evaluation and Research (CBER) granted Breakthrough Device Designation for the SCD in cardiorenal syndrome with LVAD in September 2023. “Oftentimes patients with ...
Stockhouse27d
FDA Approves Feasibility Study with SeaStar Medical's Selective Cytopheretic Device in Adults with Cardiorenal Syndrome
The FDA’s Center for Biologics Evaluation and Research (CBER) granted Breakthrough Device Designation for the SCD in cardiorenal syndrome with LVAD in September 2023 ... be able to ...
Medscape7d
Nursing Education and Implications for Left Ventricular Assist Device Destination Therapy
With FDA approval of LVAD therapy in the United States for the nontransplant population, many patients who are older than age 65 years may receive LVADs. Some may have more comorbidities and have ...